Latest News
ESGO 2026: Elenagen Phase II Data in Platinum-Resistant OC
At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...
Latest News
From Hype to Hard Science: Unlocking MSC Therapy’s Promise
After decades of promise and setbacks, advanced manufacturing platforms and robust Phase 2/3 trials are demonstrating whether MSCs can deliver transformative treatments for high-burden diseases Mesenchymal stromal cells (MSCs) have been called the most promising...
RCM Efficiency: Solving Insurance Denials & Margin Pressure
Insurance Denials and Revenue Cycle Inefficiencies Are Becoming a Primary Driver of Hospital Financial Strain U.S. hospitals are entering the next fiscal cycle under sustained financial pressure, and insurance denials have emerged as one of the most consequential, yet...
Thousands Recruited for “New Era” Severe Mental Illness Study
Thousands of people living with schizophrenia and severe depression are being recruited by the NHS for a major new study which could unlock a “new era” of personalised treatment for severe mental illness. As part of the world’s largest mental health study, researchers...
THX Pharma and Biocodex Sign Licensing Deal for Batten-1 and TX01 Therapies
THX Pharma (formerly known as Theranexus) has entered into a strategic licensing agreement with French pharmaceutical company Biocodex covering two experimental programs, Batten-1 and TX01, in a move aimed at accelerating development and expanding commercial reach....
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
The Science Behind Sleep, Exercise and Hydration Targets
For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...
Top 5 Global Diseases and Future Outlook for Life Science Innovation
The landscape of global disease continues to evolve, shaped by demographic shifts, environmental pressures, and rapid advances in biomedical innovation. For life science professionals, understanding where the world’s highest-burden diseases stand today, and where...
Investor Trends and Valuation Shifts in the Volatile Biotech Sector
The biotechnology sector is navigating a turbulent market environment in 2025. After earlier highs, many biotech companies have seen steep share-price declines, while investors remain cautious yet selective about which assets to back. As macroeconomic pressures and...
Must-Track Biomarkers
The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...
Gene and RNA Therapies Gain Momentum in Obesity Treatment
The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...
How Neurons Help Cancer Spread
One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Life Science Development in Singapore: A Rising Global Powerhouse
Singapore has rapidly transformed into one of the world’s most advanced and influential life science hubs. Over the past two decades, the city-state has combined strategic investment, world-class infrastructure, and a thriving innovation ecosystem to position itself...
Halozyme Granted Injunction Against Merck in Keytruda Patent Case
A German court has granted Halozyme a preliminary injunction that halts the sale of the subcutaneous version of Keytruda in Germany, marking a significant legal win in the companies’ high stakes patent dispute. The decision could complicate Merck’s plans for the...
Pharma 5.0: The Future of Human-Centric, Intelligent, Sustainable Medicine
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
The Science Behind Sleep, Exercise and Hydration Targets
For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...
Top 5 Global Diseases and Future Outlook for Life Science Innovation
The landscape of global disease continues to evolve, shaped by demographic shifts, environmental pressures, and rapid advances in biomedical innovation. For life science professionals, understanding where the world’s highest-burden diseases stand today, and where...
Investor Trends and Valuation Shifts in the Volatile Biotech Sector
The biotechnology sector is navigating a turbulent market environment in 2025. After earlier highs, many biotech companies have seen steep share-price declines, while investors remain cautious yet selective about which assets to back. As macroeconomic pressures and...
Must-Track Biomarkers
The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...
Gene and RNA Therapies Gain Momentum in Obesity Treatment
The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...
How Neurons Help Cancer Spread
One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...
Astatine-211: The Alpha-Emitter Gaining Momentum in Targeted Radiotherapy
Astatine, the heaviest halogen and the rarest naturally occurring element, has long been a scientific curiosity. Among its many isotopes, ²¹¹At has emerged over the past decade as a frontrunner in the quest to harness alpha particles for highly targeted radiotherapy....
Life Science Development in Singapore: A Rising Global Powerhouse
Singapore has rapidly transformed into one of the world’s most advanced and influential life science hubs. Over the past two decades, the city-state has combined strategic investment, world-class infrastructure, and a thriving innovation ecosystem to position itself...
Halozyme Granted Injunction Against Merck in Keytruda Patent Case
A German court has granted Halozyme a preliminary injunction that halts the sale of the subcutaneous version of Keytruda in Germany, marking a significant legal win in the companies’ high stakes patent dispute. The decision could complicate Merck’s plans for the...
Pharma 5.0: The Future of Human-Centric, Intelligent, Sustainable Medicine
As the pharmaceutical industry undergoes rapid transformation, a new paradigm is taking shape. Known as Pharma 5.0, it represents more than an upgrade in technology, it is a fundamental shift toward human-centric innovation, sustainable manufacturing, and intelligent...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
AI & Cloud Enabled R&D and Clinical Operations Surge in Life Sciences
Digital transformation is accelerating across the life sciences sector as more organisations adopt AI driven platforms and cloud computing to speed up drug discovery, streamline clinical trials and optimise operations. A recent industry overview from BioSpace...
Featured Articles
Further News
Autolus CAR-T Offers Hope to Adults with Aggressive Blood Cancer
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending a novel, next-generation chimeric antigen receptor T-cell (CAR-T) therapy for use in the National Health Service (NHS). This landmark decision is set to...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
US and UK Agree Zero Tariffs Deal on Pharmaceuticals
US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...
Hot Topic to Watch in China Life Sciences: Data Exclusivity & IP Reforms
China’s life sciences sector is poised for a potential regulatory shake-up this week, as stakeholders await clarity on data exclusivity and intellectual property (IP) protection reforms. Earlier this year, the National Medical Products Administration (NMPA) released a...
A Milestone in Rare Disease Genomics
Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...
Brain Cell Communication at the Molecular Level
Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...
Welcome to Life Science Daily News
Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Decision Frameworks in Pharma
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine What Works, What Kills What, and Why It Matters In pharmaceutical R&D, where billions ride on the flip of a biological coin, decision frameworks aren’t just nice-to-haves - they’re...
Follow the Science? It Would Rather Follow a Leader… (2025 Update)
Eight years on from the first version of this article, “follow the science” is still the industry’s favourite comfort blanket. It sounds noble, unassailable, the kind of thing you put on a lab-wall poster next to a photo of Rosalind Franklin. (Following the X...
Durvalumab approved in the US
Durvalumab approved in the US as first & only perioperative immunotherapy for patients with early gastric & gastroesophageal cancers! The FDA approved Durvalumab (Imfinzi) in combination with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.